news

June 28 2016
Aytu BioScience Announces Presentation of Clinical Data Highlighting Efficacy of Natesto™ (Testosterone) Nasal Gel in Men with Seasonal Allergies

June 28 2016
Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome

June 22 2016
Aytu BioScience to Execute Reverse Stock Split in Anticipation of Uplisting its Common Stock to a National Exchange


 

events

July 12-14 2016
Biotech CEO Summit

July 12-13 2016
Cantor Fitzgerald’s 2nd Annual Healthcare Conference

Aug 10-11 2016
CanaccordGenuity Growth Conference

Sept 9 2016
BioCentury's NewsMakers in the Biotech Industry


 

spotlight